Sarah J Aurit1, Susan S Devesa2, Amr S Soliman3, Catherine Schairer4,5. 1. Division of Clinical Research and Evaluative Sciences, Creighton University School of Medicine, Omaha, NE, USA. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. 3. Medical School of the City University of New York, New York, USA. 4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. schairec@exchange.nih.gov. 5. , 9609 Medical Center Drive, Rm 6E340, Rockville, MD, 20850, USA. schairec@exchange.nih.gov.
Abstract
PURPOSE: Inflammatory breast cancer (IBC) rates increased in the United States before the turn of the twenty-first century. We examine trends by estrogen receptor (ER) status since then. METHODS: Using data from the Surveillance, Epidemiology, and End Results (SEER) program for years 2001-2015, we calculated age-adjusted incidence rates for IBC (defined by AJCC TNM category T4d, extent of disease codes, and morphology code 8530) by ER status, which was imputed if unknown, among women aged 25-84 years. For comparison, we included other locally advanced breast cancer and other breast cancers partitioned into localized and regional/distant/unstaged. We fit joinpoint log-linear models to annual rates to calculate annual percentage change (APC) and average annual percentage change (AAPC). RESULTS: The rate of increase in ER+ IBC rates among women aged 25-44 (AAPC = 0.5) was similar to other advanced tumor types, but declines among women aged 45-84 (AAPC = - 2.2) were more rapid. Declines in ER- IBC rates for women aged 25-84 (AAPC = - 3.7) were more rapid than for other tumor types. CONCLUSIONS: Our results show a reversal of the rising rates of IBC overall reported at the end of the twentieth century. Direction of trends for IBC is consistent with other breast cancer types, except for ER+ localized breast cancer in older women. Decreasing parity and rising prevalence of older age at first birth may contribute to declining rates of ER- IBC. Otherwise, patterns of changing risk factors are inconsistent with the trends we observed. Further studies of IBC are necessary to identify additional risk factors and possible preventive strategies.
PURPOSE:Inflammatory breast cancer (IBC) rates increased in the United States before the turn of the twenty-first century. We examine trends by estrogen receptor (ER) status since then. METHODS: Using data from the Surveillance, Epidemiology, and End Results (SEER) program for years 2001-2015, we calculated age-adjusted incidence rates for IBC (defined by AJCC TNM category T4d, extent of disease codes, and morphology code 8530) by ER status, which was imputed if unknown, among women aged 25-84 years. For comparison, we included other locally advanced breast cancer and other breast cancers partitioned into localized and regional/distant/unstaged. We fit joinpoint log-linear models to annual rates to calculate annual percentage change (APC) and average annual percentage change (AAPC). RESULTS: The rate of increase in ER+ IBC rates among women aged 25-44 (AAPC = 0.5) was similar to other advanced tumor types, but declines among women aged 45-84 (AAPC = - 2.2) were more rapid. Declines in ER- IBC rates for women aged 25-84 (AAPC = - 3.7) were more rapid than for other tumor types. CONCLUSIONS: Our results show a reversal of the rising rates of IBC overall reported at the end of the twentieth century. Direction of trends for IBC is consistent with other breast cancer types, except for ER+ localized breast cancer in older women. Decreasing parity and rising prevalence of older age at first birth may contribute to declining rates of ER- IBC. Otherwise, patterns of changing risk factors are inconsistent with the trends we observed. Further studies of IBC are necessary to identify additional risk factors and possible preventive strategies.
Entities:
Keywords:
Incidence rates; Inflammatory breast cancer; SEER; Trends
Authors: Catherine Schairer; Shahinaz M Gadalla; Ruth M Pfeiffer; Steven C Moore; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-01-13 Impact factor: 4.254
Authors: Christopher I Li; Elisabeth F Beaber; Mei-Tzu Chen Tang; Peggy L Porter; Janet R Daling; Kathleen E Malone Journal: Breast Cancer Res Treat Date: 2012-12-09 Impact factor: 4.872
Authors: Michelle D Althuis; Jennifer H Fergenbaum; Montserrat Garcia-Closas; Louise A Brinton; M Patricia Madigan; Mark E Sherman Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-10 Impact factor: 4.254
Authors: Eren D Yeh; Heather A Jacene; Jennifer R Bellon; Faina Nakhlis; Robyn L Birdwell; Dianne Georgian-Smith; Catherine S Giess; Judi Hirshfield-Bartek; Beth Overmoyer; Annick D Van den Abbeele Journal: Radiographics Date: 2013 Nov-Dec Impact factor: 5.333